Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
Chun-Chieh WangChun-Li WangFu-Chih HsiaoMing-Shien WenChien-Ying HuangChung-Chuan ChouPao-Hsien ChuPublished in: ESC heart failure (2020)
In patients with HF with reduced ejection fraction, sacubitril/valsartan was superior to ARB therapy in reducing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular death.